• With extensive experience in conduction clinical trials, our CDM team and Medical Experts at Techsol have created a global library of Case Reports Forms (CRFs) for all major therapeutic areas. This library helped us to develop a CRF that meets sponsor study requirements and also captures critical and non-critical data points.
• Our Clinical data managers has developed a comprehensive data validation plan to validate all the critical and non-critical data points. This includes the implementation of both programmed and manual edit checks to address complex study data validation scenarios.
• Our study programmers have developed out of box solution using SAS programming to validate data for all the manual edit checks 
• Techsol has developed standard data review guidelines for this complex study to review all the lab data that is collect across the sites with multiple lab ranges. The CDM team is well-trained on this review guidelines.
• Our Safety and Monitoring Review Board conducts weekly meetings with key stakeholders to review SAE and AE-related data. They also assist the CDM team in reconciling safety data across systems.
• Techsol has implemented a comprehensive clinical data review process by establishing a QC review board, comprised of medical experts, lead data managers and quality control team and also created a quality review process, ensuring comprehensive and accurate clinical data review.

• As per the client’s requirement, we have identified and selected a vendor capable of providing EDC solutions within very short timeframe, meeting sponsor’s stringent timelines in conducting clinical study. 
• To ensure the highest quality and regulatory compliance, we validated the EDC solution in accordance with 21 CFR Part 11 guidelines for computer system validation.
• Our data management team design the CRF in accordance with the study protocol and obtained client approval. Following approval, our data management team worked closely and rigorously with the vendor’s database team to design and build study in EDC solution, adhering to industry best standards (CDISC). 
• Techsol provided various artifacts like eCRF data entry guidelines, role-based training, and documentation for EDC applications users, ensuring accurate data capture the study sites.
• Our CDM team has initiated various activities related to data cleaning and thrived hard to achieve quality. This included close collaboration with site personnel to ensure accurate data entry as per source documentation through regular follow-ups. Additional training and guidelines were provided to site users as needed. 
• In line with our SOP’s, we ensured timely responses for the discrepancies raised by data management team. To facilitate this, we conducted weekly meetings with all key business stakeholders to address any hurdles in achieving our target.
• A dedicated QC team, including designated medical monitor, lead data management personal to perform 100% data review for critical and non-critical study data points.
• CDM team worked closely with vendor in identifying the system bottlenecks and optimized the data for better performance
• Developed complex and custom dashboards and reports to support the Clinical data managers, Investigators, site coordinators, and research associates, enabling more efficient and accurate day-to-day activities. 

• To convert FHIR data to CDISC standards successfully, a comprehensive approach is needed that tackles technical and organizational aspects.
• Clinical Data Management develops transformation guidelines for convert FHIR data into the required standard format with version control, ensuring the integrity and accuracy of the transformed data. The process follows standardized formats with CDISC based on the mapping document, providing a robust verification process.
• Techsol clinical data management approached by implementing with data validation checks to identify inconsistencies, missing values or discrepancies within the FHIR data. This can involve checks for data integrity, completeness, and adherence to standards.
• Terminology Mapping: Map the terminology used in the FHIR standard to CDISC standard data vocabularies such as ICD-10 (International Classification of Diseases), develop comprehensive terminology mappings to ensure consistency and interoperability across datasets.
• Tools and Resources: Techsol’s Clinical Data Management team have developed In-house tool to export the data output with CDISC standards in human readable format and it is easy to analysis. 
• Training and Education: We have nominated qualified resource to self-learn the FHIR data standards and developed training materials and documents for software development and also provided trainings, guidance, including manuals and power point presentations for internal team and QC/QA teams.
• Data Cleaning: Implemented robust data quality checks at various stages of the data management process. This includes both API’s checks using software tools and manual checks by experienced data management team and medical experts.
• Team collaboration: Regular meetings and discussions helped to identify challenges early on and find effective solutions collectively.
• Standardization Plan: The implementation of In-house software tools, adhering to industry-standard formats and protocols, has been instrumental in maintaining data consistency and promoting interoperability.

• Our in-house statisticians develop a comprehensive and accessible randomization plan that clarifies all technical aspects for the sponsor. This plan includes a detailed description of the chosen randomization method, outlining the allocation ratio, block size, and their importance in ensuring balanced treatment groups. Additionally, it should outline the total number of subjects or vials generated, providing rationale for these choices. Regular updates throughout the trial on randomization progress and any relevant data changes can reinforce transparency. This approach ensures that the sponsor remains informed and engaged, facilitating alignment and regulatory compliance.
• Implement a stratified block randomization process by site, ensuring balance in treatment assignments within each center. Using SAS macros, create blocks specific to each site or center, controlling the allocation ratio to maintain balance.
• Plan for dropouts by generating extra randomization slots or treatment allocations. Additionally, implement an adaptive design that allows for re-randomization if necessary, or employ imputation methods to handle missing data without compromising treatment balance.
• Estimate the required number of vials based on site enrolment rates and anticipated dropouts. To avoid overproduction, used a centralized inventory management system to monitor the distribution and usage of vials across sites in real-time.
• Determined block sizes based on anticipated enrolment patterns, ensuring they are small enough to maintain balance within sites but large enough to protect blinding. Randomizing the block size (e.g., using variable block sizes) can also help reduce the predictability of treatment allocation.

• Techsol’s collaborative approach with statisticians, clinicians, and data managers ensures that SAP effectively captures primary and secondary endpoints, while meeting both regulatory and clinical requirements.
• Creating mock shells in stages, incorporating regular feedback loops from data managers and analysts. This iterative process ensured alignment and accurately reflected the SAP specifications. Version-controlled templates allow easier tracking of changes and facilitate faster resolution of misalignments.
• A strong emphasis was placed on ensuring consistency between the SAP and mock shells throughout the project. 
• Techsol developed a library of standardized mock shell templates tailored to common anxiety disorder measures, such as GAD-7. These templates include pre-set layouts for reporting scores, baseline comparisons, and patient demographics, reducing setup time and ensuring uniformity across analyses.
• Weekly review meetings were conducted to address SAP and mock shell issues promptly. This enabled the team to identify and resolve misalignments swiftly, fostering effective communication and minimizing delays. 

• Successfully resolving challenges in regulatory dossier submission and efficient query management led to the approval of the license. 
• Implementing strategies such as targeted outreach, patient-centric approaches, and proactive retention tactics enabled effective navigation of obstacles in patient recruitment and retention.
• This proactive approach ensured compliance with regulations while also enhancing participant engagement, contributing significantly to the overall execution of the study. 

• Expert Team Deployment: Assembled a cross-functional team of medical writers, statisticians, medical reviewers and regulatory experts. 
• Advanced Project Management Tools: Used tools like Gantt charts and workflow trackers to ensure timely completion of tasks. 
• Iterative Feedback Mechanisms: Fostered a collaborative environment with client team for prompt resolution of queries and feedback. 
• Comprehensive Documentation: Developed supplementary documents, including Investigator’s Brochure (IB) and informed consent forms (ICFs), to streamline subsequent trial phases.   

• Data Limitations: Unlike pharmaceutical studies, which often utilize large sample sizes and rigorous double-blind, placebo-controlled designs, nutraceutical trials sometimes lack the same level of experimental control. These trials often involve relatively small sample sizes conducted over shorter periods, limiting the robustness of the efficacy data and the ability to detect rare adverse effects. Techsol emphasized transparency regarding study limitations within the CSR by clearly stating the constraints in sample size and study design, and provided context for interpreting the results, and ensuring efficacy without overstating conclusions. Additionally, employed data visualization techniques to present the efficacy data, such as using Kaplan-Meier curves, which helped clarify results despite the data constraints. 
• Quality of Clinical Data: Nutraceutical trials may be more observational than interventional, affecting data robustness and completeness. Techsol medical writing team presented findings that were thorough and impactful, supporting strong, evidence-based conclusions that bolstered market confidence. The CSR transparently reported any limitations and included supplementary analyses, like subgroup evaluations, to provide additional insights. This approach helped create a scientifically valid and clear report, despite the constraints of observational data.  
• Scientific Skepticism: The scientific community often questions the efficacy of nutraceuticals due to their less stringent testing and approval processes compared to pharmaceuticals. Techsol team present findings in a manner that can withstand scrutiny from both the scientific community and regulatory reviewers. To address potential skepticism, Techsol provides a balanced interpretation of the results, carefully avoiding exaggerated efficacy claims. Additionally, a robust discussion section is included that compares products’s efficacy with similar nutraceuticals and references existing peer-reviewed literature to position the findings within a broader scientific context.
• Adhering to GCP Standards: Ensuring Good Clinical Practice (GCP) compliance in nutraceutical trials can be challenging, especially few nutraceutical companies may not apply the same rigorous oversight as pharmaceutical companies. Techsol strictly adheres to GCP guidelines, and conducts a detailed review of the trial documentation, collaborating with the clinical and QA teams to perform gap analysis in GCP compliance. This process ensures that the CSR provides clear evidence of adherence to GCP standards.
• Balancing Consumer Claims with Clinical Findings: Nutraceuticals are often marketed with claims that appeal to health-conscious consumers but may not fully align with the clinical data. Techsol took a conservative approach, ensuring that the CSR presented an objective interpretation of the findings without exaggeration by creating separate summaries for the general audience that balanced consumer-friendly language with scientific accuracy, clearly differentiating between observed effects and potential benefits. 

Techsol innovative and crucial solutions:  

• Techsol’s medical writing and regulatory experts meticulously reviewed regulatory guidelines and ensured compliance to streamline a path to regulatory acceptance for both international and local standards. This included designing the protocol with precise eligibility criteria, study design and endpoints.
• Techsol’s toxicology expert team used an advanced dose-conversion algorithm to translate animal model data into a clinically relevant human dose. This was validated through iterative calculations and expert review to ensure dosing was scientifically sound, minimizing risk and optimizing therapeutic outcomes.
• Our medical experts selected appropriate assessment scales for CNS-related psychiatric trials, leveraging insights from Key Opinion Leaders (KOLs) and conducting an extensive literature review with accuracy and patient safety. The scales included GAD-7 and HAM-A for measuring anxiety severity, CGI-I for evaluating overall improvement, and PSQI for assessing changes in condition and sleep quality. These scales were designed to capture the CNS-related psychiatric symptoms, enhancing the precision of clinical assessments and ensuring data quality.
• Our team developed a robust and feasible study design, clearly outlining the study objectives, inclusion/exclusion criteria, treatment groups, and endpoints. By conducting comprehensive risk assessments, our team developed a detailed activity schedule along with safety protocols to be adhered to throughout the study.